A Study of Olaratumab in Japanese Participants With Advanced Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-23

Study Completion Date

2020-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \[STS\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

NCT03994627

Soft Tissue Sarcoma

APPROVED_FOR_MARKETING

A Study of Olaratumab in Soft Tissue Sarcoma

NCT01185964

Sarcoma, Soft Tissue

COMPLETED PHASE1/PHASE2

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT03283696

Soft Tissue Sarcoma

COMPLETED PHASE1

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

NCT01199822

Malignancy Metastasis

COMPLETED PHASE1

FT538 in Subjects With Advanced Hematologic Malignancies

NCT04614636

Acute Myeloid Leukemia AML, Adult Multiple Myeloma +1 more

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A cohort 1: Olaratumab+Doxorubicin

15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met

.

Group Type EXPERIMENTAL

Olaratumab

Intervention Type BIOLOGICAL

Administered IV

Doxorubicin

Intervention Type DRUG

Administered IV

Part A cohort 2: Olaratumab+Doxorubicin

15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.

Group Type EXPERIMENTAL

Olaratumab

Intervention Type BIOLOGICAL

Administered IV

Doxorubicin

Intervention Type DRUG

Administered IV

Part A cohort 3 Olaratumab + Doxorubicin

20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.

Group Type EXPERIMENTAL

Olaratumab

Intervention Type BIOLOGICAL

Administered IV

Doxorubicin

Intervention Type DRUG

Administered IV

Part B: Olaratumab

15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

Group Type EXPERIMENTAL

Olaratumab

Intervention Type BIOLOGICAL

Administered IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olaratumab

Administered IV

Intervention Type BIOLOGICAL

Doxorubicin

Administered IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3012207 IMC-3G3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Part A: Have histological or cytological evidence of a diagnosis of advanced or metastatic solid tumor, especially STS, which is not amenable to treatment with surgery or radiotherapy. Part B: Have histological or cytological evidence of a diagnosis of solid tumor that is advanced or metastatic.
* Have the presence of measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).
* Have given written informed consent prior to any study-specific procedures.
* Have adequate organ and coagulation function
* Have an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of less than or equal to 1.
* Have discontinued previous treatments for cancer and recovered from the acute effects of therapy.
* (Part A only) Have a prestudy echocardiogram with an actual left ventricular ejection fraction greater than or equal to 50%, within 21 days prior to first dose of study medication.
* All participants agree to use a reliable method of birth control and to not donate sperm during the study and for at least 3 months following last dose of study drug.
* Female participants:

* must either be women not of child-bearing potential due to surgical sterilization confirmed by medical history, or menopause or
* women of child-bearing potential who test negative for pregnancy within 7 days before the first dose of study drug based on serum or urine pregnancy test and agree not to breast feed during the study and for 3 months following the last dose of the study drug(s)
* Have an estimated life expectancy of more than or equal to 3 months in the judgment of the investigator.

Exclusion Criteria

* Have received treatment within 21 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device for non-cancer indications or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
* (Part A only) Have received prior treatment with doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
* (Part A only) Have received prior radiation therapy to the mediastinal/pericardial area.
* Have symptomatic central nervous system malignancy or metastasis. Participants with treated central nervous system (CNS) metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants, and their disease is asymptomatic and radiographically stable for at least 60 days.
* Have an elective or a planned major surgery to be performed during the course of the study.
* Have an uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure greater than class II of the New York Heart Association guideline, severe myocardial insufficiency, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Have unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 6 months prior to study entry.
* Have a known allergy to any of the treatment components.
* Have a history of allergic reactions attributed to compounds of chemical or biologic composition similar to that of olaratumab.
* Have a known active fungal, bacterial, and/or known viral infection
* Have a corrected QT interval of greater than 470 milliseconds (msec) on screening electrocardiogram (ECG)
* Have a second primary malignancy that, in the judgment of the investigator and sponsor, may affect the interpretation of results.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No